Completed PHASE3 INTERVENTIONAL 2-arm NCT00991211

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab

Prospective Randomised Multicenter Study for Therapy Optimization (First Line) of Advanced Progredient, Low Malignant Non-Hodgkin Lymphomas and Mantle Cell Lymphomas

Sponsor: University of Giessen

Conditions Follicular Lymphomas Immunocytomas Lymphocytic Lymphomas Marginal Zone Lymphomas Non-Hodgkin Lymphomas

Interventions Bendamustine Standard chemotherapy CHOP + Ritiximab

Updated 5 times since 2017 Last updated: Aug 20, 2024 Started: Jan 31, 2004 Primary completion: Aug 31, 2009 Completion: Aug 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00991211, this PHASE3 trial focuses on Follicular Lymphomas and Immunocytomas and remains completed. Sponsored by University of Giessen, it has been updated 5 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Giessen

Data source: University of Giessen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Giessen, Germany